134 related articles for article (PubMed ID: 6345174)
21. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.
Baz R; Fanning S; Kunkel L; Gaballa S; Karam MA; Reed J; Kelly M; Hussein M
Leuk Lymphoma; 2007 Dec; 48(12):2338-44. PubMed ID: 18067008
[TBL] [Abstract][Full Text] [Related]
22. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Palumbo A; Bringhen S; Caravita T; Merla E; Capparella V; Callea V; Cangialosi C; Grasso M; Rossini F; Galli M; Catalano L; Zamagni E; Petrucci MT; De Stefano V; Ceccarelli M; Ambrosini MT; Avonto I; Falco P; Ciccone G; Liberati AM; Musto P; Boccadoro M;
Lancet; 2006 Mar; 367(9513):825-31. PubMed ID: 16530576
[TBL] [Abstract][Full Text] [Related]
23. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
24. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Facon T; Mary JY; Hulin C; Benboubker L; Attal M; Pegourie B; Renaud M; Harousseau JL; Guillerm G; Chaleteix C; Dib M; Voillat L; Maisonneuve H; Troncy J; Dorvaux V; Monconduit M; Martin C; Casassus P; Jaubert J; Jardel H; Doyen C; Kolb B; Anglaret B; Grosbois B; Yakoub-Agha I; Mathiot C; Avet-Loiseau H;
Lancet; 2007 Oct; 370(9594):1209-18. PubMed ID: 17920916
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
27. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
[TBL] [Abstract][Full Text] [Related]
28. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Wijermans P; Schaafsma M; Termorshuizen F; Ammerlaan R; Wittebol S; Sinnige H; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst H; Sonneveld P;
J Clin Oncol; 2010 Jul; 28(19):3160-6. PubMed ID: 20516439
[TBL] [Abstract][Full Text] [Related]
29. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M
Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106
[TBL] [Abstract][Full Text] [Related]
30. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden.
Ahre A; Björkholm M; Mellstedt H; Brenning G; Engstedt L; Gahrton G; Gyllenhammar H; Holm G; Johansson B; Järnmark M
Cancer Treat Rep; 1984 Nov; 68(11):1331-8. PubMed ID: 6388832
[TBL] [Abstract][Full Text] [Related]
31. Treatment of multiple myeloma with interferon alpha: the Scandinavian experience.
Mellstedt H; Osterborg A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Juliusson G
Br J Haematol; 1991 Oct; 79 Suppl 1():21-5. PubMed ID: 1931703
[TBL] [Abstract][Full Text] [Related]
32. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden.
Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
Eur J Haematol; 1993 Feb; 50(2):95-102. PubMed ID: 8440364
[TBL] [Abstract][Full Text] [Related]
33. Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden.
Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Johansson B
Acta Oncol; 1990; 29(6):727-31. PubMed ID: 2223143
[TBL] [Abstract][Full Text] [Related]
34. A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.
Bladé J; San Miguel J; Alcalá A; Maldonado J; García-Conde J; Moro MJ; Sanz Sanz MA; Alonso C; Zubizarreta A; Besses C
Blut; 1990 Jun; 60(6):319-22. PubMed ID: 2198075
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Cakana A; van de Velde H; Richardson PG;
N Engl J Med; 2008 Aug; 359(9):906-17. PubMed ID: 18753647
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
[TBL] [Abstract][Full Text] [Related]
37. Alternating combination chemotherapy COP (cyclophosphamide, vincristine, prednisone) and MP (melphalan, prednisone) in multiple myeloma: a multicenter phase II study (JCOG8906). Lymphoma Study Group of the Japan Clinical Oncology Group.
Takenaka T; Shirakawa S; Mikuni C; Sai T; Shimamoto Y; Araki K; Hirano M; Miura A; Ohno Y; Ichimaru M; Hanada S; Inaba S; Konishi H; Toki H; Tajima K; Niimi M; Fukuda H; Shimoyama M
Jpn J Clin Oncol; 1999 Oct; 29(10):485-9. PubMed ID: 10645803
[TBL] [Abstract][Full Text] [Related]
38. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
Mateos MV; Oriol A; Martínez-López J; Teruel AI; Bengoechea E; Palomera L; de Arriba F; Esseltine DL; Cakana A; Pei L; van de Velde H; Miguel JS
Ann Hematol; 2016 Dec; 95(12):2033-2041. PubMed ID: 27738789
[TBL] [Abstract][Full Text] [Related]
39. Induction treatment with alpha-interferon in multiple myeloma: an interim report from MGCS.
Mellstedt H; Osterborg A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Johansson B
Eur J Haematol Suppl; 1989; 51():124-8. PubMed ID: 2697585
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors and treatment of multiple myeloma: interest of a cyclic sequential chemohormonotherapy combining cyclophosphamide, melphalan, and prednisone.
Belpomme D; Simon F; Pouillart P; Amor B; Feuilhade de Chauvin F; Belpomme A; Menkes C; Delrieu A; Depierre R; Le Mevel B; Serrou B; Fries D; Delbarre F; Mathé G
Recent Results Cancer Res; 1978; 65():28-40. PubMed ID: 746249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]